Nonlymphomatous hepatobiliary masses in cats: 41 cases (1972 to 1991).
The medical and necropsy records of 41 cats diagnosed with nonlymphomatous hepatobiliary (NLHB) masses, including neoplasia and cysts, were reviewed. Overall, benign masses (n = 27) were more common than malignant ones (n = 14). The single most common malignancy was cholangiocellular carcinoma. The median age at diagnosis was significantly lower (P < .01) for cats with malignant rather than benign disease. Clinical signs associated with hepatobiliary neoplasia were usually vague and included lethargy, vomiting, and anorexia, often present for at least 2 weeks before presentation. Benign masses were an incidental finding in significantly more (P < .01) of the cases than were malignant masses. Median values for alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin were significantly higher (P < .05) in cats with malignant versus benign masses. The prognosis for malignant disease was poor, with 86% of the cats dying or being euthanatized during hospitalization. Cats with benign disease that underwent exploratory celiotomy were more likely to recover and warranted a more favorable prognosis than cats with malignant tumors. Factors associated with malignancy included age at presentation, presence of clinical signs at presentation, and specific serum chemistry changes.
Lawrence
H J
HJ
Department of Clinical Sciences, New York State College of Veterinary Medicine, Cornell University, Ithaca.
Erb
H N
HN
Harvey
H J
HJ
D002759:Adenoma, Bile Duct / Q000453:epidemiology / Q000601:surgery / Q000662:veterinary; D018248:Adenoma, Liver Cell / Q000453:epidemiology / Q000601:surgery / Q000662:veterinary; D000410:Alanine Transaminase / Q000097:blood; D000469:Alkaline Phosphatase / Q000097:blood; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D001660:Biliary Tract Diseases / Q000453:epidemiology / Q000601:surgery / Q000662:veterinary*; D001661:Biliary Tract Neoplasms / Q000453:epidemiology / Q000601:surgery / Q000662:veterinary*; D001663:Bilirubin / Q000097:blood; D006528:Carcinoma, Hepatocellular / Q000453:epidemiology / Q000601:surgery / Q000662:veterinary; D002371:Cat Diseases / Q000453:epidemiology* / Q000601:surgery; D002415:Cats; D018281:Cholangiocarcinoma / Q000453:epidemiology / Q000601:surgery / Q000662:veterinary; D002784:Cholesterol / Q000097:blood; D003560:Cysts / Q000453:epidemiology / Q000601:surgery / Q000662:veterinary; D005260:Female; D005354:Fibrosarcoma / Q000453:epidemiology / Q000601:surgery / Q000662:veterinary; D006394:Hemangiosarcoma / Q000453:epidemiology / Q000601:surgery / Q000662:veterinary; D008107:Liver Diseases / Q000453:epidemiology / Q000601:surgery / Q000662:veterinary*; D008113:Liver Neoplasms / Q000453:epidemiology / Q000601:surgery / Q000662:veterinary*; D008297:Male; D009518:New York / Q000453:epidemiology; D011379:Prognosis; D012189:Retrospective Studies; D018709:Statistics, Nonparametric; D016896:Treatment Outcome
D002784:Cholesterol; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D000469:Alkaline Phosphatase; D001663:Bilirubin